GPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells
Abstract Chronic myeloid leukemia (CML) harboring BCR/ABL-T315I mutation has been a challenging obstacle for targeted therapy due to the acquired resistance to tyrosine kinase inhibitor (TKI)-based therapy. Thus, it is especially urgent to investigate more effective therapeutic targets to overcome T...
Saved in:
| Main Authors: | Jun-Dan Wang, Jin-Xing Wang, Zhi-Li Lin, Na Xu, Ling Zhang, Jia-Jun Liu, Rui Gao, Zi-Jie Long |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2025-05-01
|
| Series: | Cell Death Discovery |
| Online Access: | https://doi.org/10.1038/s41420-025-02502-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of Clinical Features and Hematological Laboratories between Ph (+)/BCR-ABL (+) Chronic Myeloid Leukemia and Other Type of Ph/BCR-ABL Chronic Myeloid Leukemia
by: Wulyo Rajabto, et al.
Published: (2018-03-01) -
Fungal secondary metabolites as a potential inhibitor of T315I- BCR::ABL1 mutant in chronic myeloid leukemia by molecular docking, molecular dynamics simulation and binding free energy exploration approaches
by: Dilinazi Abulaiti, et al.
Published: (2024-12-01) -
Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations
by: Benedetta Mariotti, et al.
Published: (2019-01-01) -
BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01) -
Prognostic Significance of Transcript-Type BCR‐ABL1 in Chronic Myeloid Leukemia
by: matteo molica, et al.
Published: (2020-08-01)